What Happened?
Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ: NEO) jumped 3.6% in the pre-market session after the company announced an executive succession plan alongside preliminary updates that pointed to higher full-year guidance.
Under the leadership transition outlined in an SEC Form 8-K filing, President and Chief Operating Officer Warren Stone will become CEO on January 4, 2027. Incumbent CEO Tony Zook will transition to Executive Chairman, while Michael Kelly was named Lead Independent Director. Alongside the handover, NeoGenomics projected preliminary unaudited third-quarter revenue of approximately $209 million. Next-generation sequencing revenue grew roughly 28% year over year, prompting the company to confirm in its press release that full-year revenue guidance is expected to increase at the midpoint.
Following the company's announcements, BTIG analyst Mark Massaro upgraded NeoGenomics to Buy and set a Street-high $28 price target, implying roughly 46% upside, in research tracked by TipRanks. Executive handovers can often invite uncertainty, but pairing an orderly succession with higher revenue expectations helps reinforce investor confidence in sustained operational momentum.
After the initial pop, the shares cooled down to $17.36, down 9.1% from the previous close.
Is now the time to buy NeoGenomics? Access our full analysis report here, it’s free.
What Is The Market Telling Us
NeoGenomics’s shares are very volatile and have had 27 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The biggest move we wrote about over the last year was 2 months ago when the stock gained 15.8% on the news that the company reported second-quarter 2026 earnings that surpassed Wall Street expectations and raised its full-year financial guidance.
The cancer-diagnostics company posted adjusted earnings of $0.05 per share on revenue of $201.7 million, beating analyst forecasts of $0.03 per share and $197.3 million in revenue. The top-line result represented an 11.2% increase compared to the same period in the previous year. Following the strong performance, NeoGenomics lifted its full-year outlook, now expecting revenue of around $804 million. Furthermore, its adjusted earnings per share guidance for the full year of $0.19 also came in ahead of analyst estimates.
NeoGenomics is up 47.6% since the beginning of the year, but at $17.36 per share, it is still trading 12.8% below its 52-week high of $19.91 from September 2026. Despite the year-to-date gain, investors who bought $1,000 worth of NeoGenomics’s shares 5 years ago would now be looking at only $403.79.
ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who’s building AI, one company is already using it to print money. And nobody’s paying attention.
AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won’t last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice.
